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Sphingosinekinase(SphK)exhibitstwoisoforms,SphK1andSphK2.Bothformscatalyzethesynthesisofsphingosine1-phosphate
(S1P), a sphingolipid involved in ischemic preconditioning (IPC). Since the ratio of SphK1:SphK2 changes dramatically with
aging, it is important to assess the role of SphK2 in IR injury and IPC. Langendorﬀ mouse hearts were subjected to IR (30min
equilibration,50minglobalischemia,and40minreperfusion).IPCconsistedof2minofischemiaand2minofreperfusionfortwo
cycles. At baseline, there were no diﬀerences in left ventricular developed pressure (LVDP), ±dP/dtmax, and heart rate between
SphK2 null (KO) and wild-type (WT) hearts. In KO hearts, SphK2 activity was undetectable, and SphK1 activity was unchanged
compared to WT. Total SphK activity was reduced by 53%. SphK2 KO hearts subjected to IR exhibited signiﬁcantly more cardiac
damage (37 ± 1% infarct size) compared with WT (28 ± 1% infarct size); postischemic recovery of LVDP was lower in KO hearts.
IPC exerted cardioprotection in WT hearts. The protective eﬀect of IPC against IR was diminished in KO hearts which had much
higher infarction sizes (35 ± 2%) compared to the IPC/IR group in control hearts (12 ± 1%). Western analysis revealed that KO
hearts had substantial levels of phosphorylated p38 which could predispose the heart to IR injury. Thus, deletion of the SphK2
gene sensitizes the myocardium to IR injury and diminishes the protective eﬀe c to fI P C .
1.Introduction
Exposureofthemyocardiumtoextendedperiodsofischemia
resultsincellinjury.Muchofthisdamageoccursuponreper-
fusion, and thus it is referred to as ischemia/reoxygenation
(I/R) injury. Reactive oxygen species are formed upon
reperfusion, and they have been implicated as contributing
factors to this injury [1]. I/R injury is characterized by
poor recovery of hemodynamic function upon reperfusion
and the development of extensive areas of infarction [2].
Protection against I/R injury can be provided by ischemic
preconditioning (IPC). IPC consists of short periods of
I/R that precede long term (index) ischemia and reper-
fusion. The triggers for IPC are cellular agonists that are
released from myocytes via pannexin-1/P2X7 channels [3]
in response to brief ischemia. These agonists bind to G-
protein coupled receptors initiating a protective response [4–
6]. These include adenosine, bradykinin, and opioids [4, 5]
and sphingosine-1-phosphate (S1P) [6].
S1P is an important intracellular signaling molecule that
regulates diverse cellular events and has both cell growth
and prosurvival eﬀects [7–9]. These cell signaling eﬀects
are in part mediated by S1P binding to speciﬁc cell surface
G-protein-coupled receptors [7–10]. In the heart, S1P is2 Oxidative Medicine and Cellular Longevity
cardioprotective as revealed by studies of cultured cardiac
myocytes [11, 12]a sw e l la sex vivo isolated hearts [3, 6, 13].
The increased myocyte viability induced by S1P may relate
to activation of a prosurvival pathway that includes PI-
3K/Akt and increased bcl-2 expression followed by reduced
cytochrome C release and prevention of caspase activation
[9, 12].
Sphingosine kinase (SphK) is the enzyme responsible
for the formation of S1P. It exhibits two isoforms (SphK1
and SphK2) in heart [14–16]. SphK1 appears to be a
protective kinase, as its overexpression increases intracellular
S1P content and promotes cell growth and survival [17–19].
Indeed,studyofanSphK1nullmousedemonstratedthatloss
of SphK1 sensitizes the myocardium to I/R injury and results
in the loss of both ischemic preconditioning and ischemic
postconditioning [20, 21].
The role of SphK2 in cell survival is less clear. Studies
of SphK2 in cell systems have suggested that SphK2 is
antiproliferative and proapoptotic [22–24]. In contrast, it
has recently been shown that SphK2-directed S1P synthesis
in mitochondria is important for proper assembly of the
respiratory chain [25], and thus SphK2 activity might serve
to limit free radical production by the respiratory chain. In
thisscenario,SphK2wouldactuallybeprotective.Discerning
the role of SphK2 is important particularly with respect to
aging as we have found that SphK2 activity, but not SphK1,
decreases with aging [26]. However, to date, no studies of the
role of Sphk2 in cellular injury to heart have been reported.
Thus,theprimaryobjectiveofthepresentstudywastoutilize
mouse hearts that possess an inactivated SphK2 gene to
determine ifSphK2aﬀectssensitivity tomyocardialIRinjury
or cardioprotection conferred by IPC.
2. Results
2.1.BaselineCharacteristics. ThebaselineparametersforWT
a n dS p h K 2K Om o u s eh e a r t sa r en o td i ﬀerent. For WT and
KO, respectively, there were no diﬀerences in body weight
(25.4±1.2gversus25.9±1.8g),heartweight(93±20 versus
100 ± 20mg), heart rate (435 ± 57 versus 443 ± 59bpm),
or left ventricular developed pressure (LVDP) at baseline
(106 ± 4 versus 109 ± 10mmHg). The KO mice exhibit no
evident phenotype, breed normally, have normal vascular
development, and live a normal lifespan.
2.2. Veriﬁcation of Deletion of SphK2 and Loss of SphK2
Activity. PCR analysis of DNA from tail snips (Figure 1)
revealed that the SphK2 null hearts are indeed lacking
a full length SphK2 gene. Hearts from SphK2 null mice
and WT mice were subfractionated into cytosolic and
particulate fractions and assayed for total sphingosine kinase
activity (Figure 2). WT mice had a cytosolic speciﬁc activ-
ity of 5.63 ± 1.4pmol/min/mg protein and a particulate
fraction activity of 0.6 ± 0.2pmol/min/mg. In contrast,
KO hearts had a cytosolic speciﬁc activity of 2.65 ±
0.32pmol/min/mg protein and a particulate fraction activity
of 0.3 ± 0.08pmol/min/mg. Total activity was reduced
by approximately 53% in KO hearts relative to the wild-
type hearts (53% reduction in the cytosolic fraction and
50% reduction in the particulate fractions). There was no
change in the distribution of activity between cytosolic and
particulate fractions with ca. 85% of total activity being
present in the cytosolic fraction of both KO and WT hearts.
The ﬁnding of SphK activity in the particulate fraction of KO
hearts is consistent with the report of SphK activity in the
mitochondria from SphK2 KO hearts [25].
To verify that SphK2 activity was absent in KO hearts, we
took advantage of our previous ﬁnding that cytosolic SphK1
and SphK2 activity in heart can be cleanly separated by
gel ﬁltration chromatography [16]. Analysis of the cytosolic
fractions from WT and SphK2 KO hearts by gel ﬁltration
analysis is shown in Figure 3. As expected, SphK2 KO hearts
are completely devoid of cytosolic SphK2 activity, but SphK1
activity is not signiﬁcantly altered.
2.3. Deletion of SphK2 Impairs Cardiac Function during
Ischemia/Reoxygenation(IR)Injury. BothWTandKOhearts
were subjected to 50 min global ischemia and 40 minutes
of reperfusion (reoxygenation). The recovery of LVDP at the
e n do fI Ri ss h o w ni nFigure 4. While there was wide varia-
tioninrecoveriesofLVDPduetostunning,basedononeway
ANOVA there still was signiﬁcantly lower recovery of LVDP
i nK Om o u s eh e a r t s( 8±2 % )t h a ni nW Th e a r t s( 2 2± 9%).
Thus, IR caused more serious impairment of both cardiac
hemodynamic function in KO hearts compared to the dys-
functionobservedinheartsfromWTmice.Moreover,infarct
size was signiﬁcantly higher in KO hearts than in WT hearts
(37 ± 1% for KO versus 28 ± 1%, in WT, n = 5, P<. 05).
2.4. Deletion of SphK2 Prevents Cardioprotection during
Ischemia/Reoxygenation Injury and Ischemic Preconditioning.
As shown in Figure 4, ischemic preconditioning (IPC)
increased cardiac performance in WT hearts. At the end
of IR, WT-IPC hearts exhibited improved LVDP (66 ± 5%
recovery) compared with the WT control group (22 ± 9%).
In WT hearts infarct size was far less after IPC + IR (9 ±
2%) compared with IR alone (28 ± 1%). However, with KO
hearts IPC did not provide protection. Infarct size was not
diminished (35 ± 2% after IPC compared to 37 ± 1% for
untreated) and was much greater than that seen with IPC-
treated WT hearts (9 ± 2%). Further, recovery of LVDP was
not signiﬁcantly diﬀerent ± IPC for KO hearts (8 ± 2% no
IPC versus 20 ± 14% plus IPC) and was signiﬁcantly less
than LVDP obtained with IPC-treated WT hearts (66 ± 5%,
n = 4, P<. 05).
2.5. Exogenous Sphingosine-1-Phosphate Exerts Cardiopro-
t e c t i o ni nS p h K 2K OH e a r t s .Previous results from our
laboratory in [13, 20, 27] revealed that WT mouse hearts can
be pharmacologically preconditioned with S1P. The data in
Figure 4 indicate that pharmacological preconditioning with
0.4μMS1P protected SphK2 n u l lm o u s eh e a r t sa g a i n s tI R
injury. S1P improved LVDP recovery (63 ± 2% versus 22 ±
9% untreated) and signiﬁcantly reduced infarction size (13±
1% versus 28±1% untreated). This indicates that the signal-
ing pathway for preconditioning is still intact in KO hearts.Oxidative Medicine and Cellular Longevity 3
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Figure 1: PCR Primers showing ampliﬁcation of SphK2 from wild-type (+/+ )a n dn u l l( −/−) mice. The WT primer was used for the
identiﬁcation by PCR of the wild-type gene, and the KO primer was used for the detection of the null genotype. See Section 4 for details.
E x o n sa r es h o w na sg r e yr e c t a n g l e s .
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Figure 2:Sphingosinekinaseactivity(SKase)inWTandKOhearts.
Hearts from WT and KO hearts were ﬂushed free of blood and then
subfractionated into cytosolic and particulate fraction as described
in Section 4. The fractions were assayed for SKase activity which
is expressed as pmoles per min per mg fraction protein and reveal
reduced activity in the KO fractions (∗P<. 05 versus WT, n = 5).
2.6. Phosphorylation Levels of Akt, Erk, and p38 and in
Wild-Type and SphK2 KO Hearts. Phosphorylated forms
of the signaling molecules Akt (P-Akt) and Erk (P-Erk)
enhance survival in mouse heart. Therefore, their levels were
measured by Western blotting in untreated ﬂushed hearts
from WT and KO mice. P-Akt was readily detectable in
the cytosolic fraction of KO and WT hearts (Figure 5). No
diﬀerence in P-Akt level was observed between WT and KO
hearts (Figure 5) .P - A k tw a sp r e s e n ti nv e r yl o wa m o u n t s
in the particulate fraction from both WT and KO hearts
(data not shown). P-Erk levels exhibited wide scatter, and
mean values did not seem to diﬀer between WT and KO
hearts (data not shown). The detrimental signaling molecule
phospho-p38 (P-p38) is present in WT mouse heart in low
amount under normal conditions (Figure 5). By contrast, in
KO hearts much higher levels of P-p38 were found in the
cytosolic fraction (Figure 5). P-p38 protein was not readily
detectable in the particulate fraction of WT or KO hearts.
3. Discussion
Basedonstudiesinnoncardiaccells,ithasbeenhypothesized
that SphK1 and SphK2 have opposite eﬀects on cell survival
with SphK1 being prosurvival while SphK2 is purported
to be antisurvival [22–24]. We have previously shown in
SphK1 KO mouse hearts that an active SphK1 is essential
to cardioprotection by both ischemic preconditioning [20]
and ischemic postconditioning [21]. In the current study,
we have for the ﬁrst time examined the role of SphK2 in
cardioprotectionbytestingthehypothesisthateliminationof
SphK2 by genetic means would enhance the cardiac response
to IR injury and IPC. For these studies we used a mouse
model in which deletion of exons 2–5 of the SphK2 gene
leads to a complete loss of SphK2 activity and thereby a
>50% reduction of SphK activity in both the cytosolic and
particulate fractions. A signiﬁcant compensatory increase
in SphK1 activity was not found. We found no signiﬁcant
diﬀerence in baseline cardiac function between wild-type
and SphK2 null mouse hearts. However, after 40 minutes of
global ischemia and 40 minutes of reperfusion, recovery of
LVDP was signiﬁcantly decreased in KO hearts, and infarct
sizes were signiﬁcantly increased. This indicates an increased
sensitivity to IR injury in KO hearts. Consistent with this
increased sensitivity, the capacity for IPC-induced cardiac
protection was abolished in the KO hearts. In contrast to
studies is isolated cells [22–24], these results provide the
ﬁrst evidence in a genetically modiﬁed animal that SphK2
is an important lipid kinase mediating cardiac cell survival,4 Oxidative Medicine and Cellular Longevity
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Figure 3: Gel ﬁltration proﬁle of cytosolic SKase Activity from WT
and KO hearts. The cytosolic fraction isolated from pooled mouse
hearts from WT (-•-) and KO (-◦-) hearts were chromatographed
on a Sephacryl S200 gel ﬁltration column. The eluted fractions were
assayed for SphK activity as described in Section 4, and activity is
expressed as cpm of S1P formed per min per 0.1mL of fraction.
The proﬁle is representative of 3 separate experiments and reveal
that SphK2 activity is not present in the cytosols from the SphK 2
KO hearts.
and further that SphK1 and SphK2 are both required for
ischemic preconditioning in the heart. A protective role for
SphK2 was also reported in renal IR injury [28]. However,
ischemic preconditioning was not studied, and exogenous
S1P receptor agonism failed to produce renal protection
[28].
IPC results in release of S1P from myocytes which
then binds to cell surface G-protein-coupled receptors and
triggers the cardioprotective response [3, 6, 29]. It follows
t h a td e l e t i o no fS p h K 2m i g h tm a k el e s sS 1 Pa v a i l a b l ef o r
release during brief episodes of IPC. We have shown that a
decrease in S1P response makes a signiﬁcant contribution to
overall potency of the preconditioning response [6]. Further,
ourpreviousworkrevealedthatduringischemia/reperfusion
injury in isolated hearts, SphK activity declines markedly
during ischemia and remains depressed during recovery,
while in hearts that have been preconditioned, recovery
of enzyme activity is much more robust [30]. S1P levels
are altered in parallel [30], and there may be a threshold
concentration at the cellular level below which prosurvival
pathways are either not activated or are suppressed. Thus,
the simplest explanation for the failure of SphK2 KO mice
to precondition is that there is insuﬃcient intracellular S1P
to achieve threshold levels of S1P release for triggering IPC
(see Figure 6).
In addition, interactions of SphK2 and/or S1P with
other signaling molecules may also contribute to the loss
of cardioprotection. In particular, Strub et al. have shown
that mitochondrial SphK2 activity is critical for the proper
assembly of cytochrome oxidase [25]. SphK2 KO mice
contain a defective cytochrome oxidase that limits respi-
ration. Decreased cytochrome oxidase activity can cause
accumulation of electrons upstream, and this can lead
to increased ROS generation [31]. Opening of the mito-
chondrial permeability transition pore (mPTP) is thought
to be the key to reperfusion injury, and ROS generation
encourages mPTP opening [32]. Therefore, increased ROS
generation upon reoxygenation by SphK2 KO hearts could
promote mPTP opening and increase subsequent injury.
This would provide a link between loss of SphK2 and IR
injury (see Figure 6).
These ﬁndings have important implications with regard
to the aging heart. As shown in Figure 3 and demonstrated
previously [16, 20, 26], in young rodent hearts, SphK2
a c t i v i t ye x c e e d st h a to fS p h K 1 ,b u ta sa n i m a l sa g et h i sr a t i o
changes so that senescent rat hearts contain signiﬁcantly
more SphK1 than SphK2 activity [26]. The data in the
present paper indicate that this shift from SphK2 to SphK1
is unlikely to aﬀect cardioprotection per se. However, this
shiftdoesappeartoleadtosomewhatreducedS1Plevelswith
aging [26], and this may contribute to the impaired response
to certain cardioprotective interventions such as IPC that
have been noted in aged hearts [26, 33, 34].
Activation of Akt by phosphorylation plays an important
role in promoting cardiomyocyte survival. Akt phosphoryla-
tion is cardioprotective both in vitro and in vivo [35, 36]. In
this study, we found that the phosphorylation levels of Akt
(and also Erk) were the same in SphK2-KO mouse hearts
at baseline as in WT. However, the detrimental signaling
molecule phospho-p38 was readily detectable in KO hearts
at baseline, but low in WT hearts. This ﬁnding implies that
chronic activation of p38 is present in the KO mouse. This
observation is novel as it has been shown that preventing
p38 phosphorylation is an important component of car-
dioprotection [37]. Chronic activation of p38 represents a
negativepredispositionoftheKOheartstoinjury.Thiscould
contribute to the adverse response of SphK2 KO hearts to IR
and IPC.
In summary, our data demonstrate for the ﬁrst time that
myocardial damage is enhanced after ischemia/reperfusion
in mice null for SphK2 and that the cardioprotective
intervention of preconditioning is abolished by deletion in
the SphK2 gene. These observations are contrary to prior
suggestions derived from in vitro models that SphK1 and
SphK2 drive opposing functions that regulate cell fate.
4.MaterialsandMethods
This study was conducted in accordance with the Guide
for the Care and Use of Laboratory Animals (National
Academic Press, Washington DC, 1996), and all procedures
were approved by the Animal Care Subcommittee of the
San Francisco Department of Veterans Aﬀairs Medical
Center. Aprotinin, leupeptin, pepstatin A, and triphenylte-
trazolium chloride (TTC) were obtained from Sigma. D-
Erythro-sphingosine 1-phosphate (S1P) was obtained from
Biomol Research Laboratories. D-Erythro-sphingosine-[3H]
was obtained from American Radiolabeled Chemicals.Oxidative Medicine and Cellular Longevity 5
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Figure 4: Hemodynamic function and infarct sizes in wild-type and SphK2 KO (SK2KO) hearts in ischemia-reoxygenation injury and
ischemic preconditioning. Equilibrated ex vivo hearts were exposed to 40min of ischemia followed by 40min of reoxygenation either in the
absence of any preconditioning (−IPC ) or with ischemic preconditioning (+IPC) or with pharmacologic preconditioning using 0.4μM S1P
(+S1P). Data are expressed as mean±SEM. ∗P<. 05 versus −IPC. n = 5–7/group. (a) Maximum left ventricular developed pressure (LVDP)
achieved during 40min of reperfusion expressed as % recovery relative to the preischemic value. LVDP is shown for wild-type (WT) and
SphK2 knockout (SK2KO) mouse hearts. (b) Infarct size expressed as percent of the area at risk (which is the total heart area in this global
ischemia model) determined at the end of 40min of reperfusion in wild-type (WT) and SphK2 knockout (SK2KO) hearts.
P-Akt
P-p38
GAPDH
KO HET WT
Figure 5: Levels ofphospho-Akt(P-Akt)and phospho-p38(P-p38)
in wild-type (WT), heterozygous (HET), and SphK2-knockout
(KO) mouse hearts. P-Akt and P-p38 levels were determined by
Western analysis in the cytosolic fractions from 4 KO hearts (lanes
1–4), 4 WT hearts (lanes 6–9), and 1 HET heart (lane 5). GAPDH:
glyceraldehyde phosphate dehydrogenase.
4.1. SphK2 Null Mice. SphK2 null (KO) mice in which exons
2–5 of the SphK2 gene had been deleted [38] were obtained
fromDrs.ShaunCoughlinandRajitaPappu(Cardiovascular
Research Institute, University of California, San Francisco).
These mice along with their wild-type littermates were
used for all studies reported herein and were all 3 to 4
months of age at the time of study. Male homozygous null
(SphK2−/−) and wild-type (WT) mice were generated by
breeding heterozygous (SphK2+/−) mice. Genotyping using
PCR to conﬁrm the absence of exons 2–5 of SphK2 DNA was
routinely performed on tail biopsies of 3-4-week-old mice.
Figure 1 shows PCR primers used for analysis of SphK2+/+,
SphK2+/−,S p h k 2 −/− mice. To identify WT and KO mice,
PCR was employed using the following primer sets. For the
WT, the set was 5 ATTTTCTGGAGGGCGGGATAGG3  and
5 AAGAGGAACGGGGAGTGAGACAAG3 , which ampliﬁes
a 572-bp fragment. The homozygous null (SphK2−/−)m i c e
were identiﬁed with the primer set as follows: 5 GCCACC-
ACTTATGAGGAGAATCG3  and5 GACACAGAACATCCC-
ATCCCTAAC3 . This set ampliﬁes a fragment of approxi-
mately 378bp.
4.2. Langendorﬀ Isolated Perfused Heart Preparation. Male
mice(3-4monthsofage,weighing25–28g)wereheparinized
(500U/kg, IP) and anesthetized with sodium pentobarbital
(60mg/kg, IP). Hearts were rapidly excised, washed in ice-
cold arresting solution (NaCl 120mmol/L, KCl 30mmol/L),
and cannulated via the aorta on a 20-gauge stainless
steel blunt needle. Hearts were perfused at 70mmHg on
a modiﬁed Langendorﬀ apparatus using Krebs-Henseleit
solution containing (mmol/L) NaCl 118, KCl 4.7, CaCl2 2.5,
MgSO4 1.2, KH2PO4 1.2, NaHCO3 24, glucose 5.5, and Na
pyruvate 5.0. The perfusion solution was bubbled with 95%
O2/5% CO2 and maintained at 37◦C. During periods of
global ischemia the hearts were lowered into a thermostated
chamber to maintain a heart temperature of 37◦C.
4.3. Ischemia-Reoxygenation (IR) and Ischemic Precondi-
tioning (IPC) Protocols. The protocol for IR experiments
consisted of a 20-minute equilibration period, followed by
40 minutes of global ischemia and 40 minutes of reperfusion
(reoxygenation). For IPC, hearts were equilibrated for 16
minutes and then subjected to two short cycles of precon-
ditioning, each consisting of 2 minutes of global ischemia
and2minutesofreperfusion.Thiswasfollowedimmediately
by 50min of global ischemia and 40min of reperfusion.
Hemodynamics (left ventricular developed pressure (LVDP),
LV end-diastolic pressure (LVEDP), and ±dP/dt)w e r e6 Oxidative Medicine and Cellular Longevity
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Figure 6: Suggested pathways for the increased susceptibility of SphK2 KO hearts to ischemia-reperfusion injury and decreased sensitivity
to ischemic preconditioning. Ischemic preconditioning of wild-type (WT) hearts leads to the release of sphingosine 1-phosphate (S1P) via
pannexin-1 (Px1) /P2X7 channels, and this S1P then binds to G-protein-coupled receptors (GPCRs) triggering cell signaling pathways that
are protective in ways that include preventing the opening of the mitochondrial permeability transition pore (mPTP), which is known to
trigger cell injury. In the Sphk2 KO hearts, the level of S1P is reduced below the threshold necessary to trigger protective cell signaling
pathways. The mPTP can also be opened by increased mitochondrial accumulation of Ca2+, and this can be enhanced by reactive oxygen
species(ROS).InSphK2KOhearts,theabsenceofadequatelevels ofS1Pleadstodefective cytochromeoxidase(COX)assemblywhichcould
lead to the generation of ROS that likely supports mPTP opening.
recorded using a balloon inserted into the LV as previously
described [20]. LVEDP was initially set at 5mmHg during
equilibration and subsequent changes measured. Infarct size
was measured by TTC staining as previously described [20].
4.4. Sphingosine Kinase Activity. Hearts were rapidly excised
from anesthetized mice (pentobarbital sodium 60mg/
mLip), mounted on the Langendorﬀ apparatus, and ﬂushed
for 1min with perfusion buﬀer. They were then homoge-
nized in ice-cold isolation buﬀer (0.13MKCl, 20mMHepes,
pH 7.4, 1mMEGTA, 1μg/L leupeptin, 0.25μg/L each of chy-
mostatin and pepstatin A). The homogenate was centrifuged
f o r6 m i na t3 5 0 gi naT O M Ym i c r o c e n t r i f u g et or e m o v e
cell debris and nuclei. The supernatant was centrifuged for
50min at 100,000g. The supernatant was decanted and
designated as the cytosolic fraction. The particulate fraction
was washed once with buﬀer A and then repelleted by
centrifugation. The wash was added back to the cytosolic
fraction. Both cytosolic and membrane fractions were used
separately for assay of SphK activity. The radioassay uses
a chloroform (fresh)/methanol/aqueous trisodium EDTA
extraction system to separate reactant ([3H]sphingosine)
from product ([3H]S1P) essentially as previously described
[30, 39]. A standard assay contains Triton X-100 (0.05%),
250mMKCl, 1μM [3H]sphingosine (300–400cpm/pmol),
5mMA TP ,10mMMg 2+,100mMT ris,pH8.0,10mMascor -
bate, and enzyme protein in a volume of 0.5mL. Separation
and identiﬁcation of enzymatically active forms of SphK1
and SphK2 were done as described previously [16].
4.5. Western Analysis. M o u s eh e a r t sw e r em o u n t e do nt h e
Langendorﬀ apparatus and perfused under the indicated
conditions. They were then homogenized in 0.13M KCl,
20mM HEPES pH 7.4, 1mM EGTA, 1μg/L leupeptin,
0.25μg/L each of aprotinin and pepstatin A and centrifuged
at 100,000×g to generate a particulate and a cytosolic
fraction. The particulate fraction was washed once with
the isolation buﬀer. Western analysis was conducted as
described previously [26] using the following antibodies
from Cell Signaling Technology: phospho-Akt (Ser 473,
no. 9271), phospho-p38 (Thr180/Tyr182, no. 9211), p38
(no. 9218), phospho-Erk1/2 (Thr202/Tyr204. no. 4376).
Protein concentration was determined using the detergent
compatible DC Protein Assay kit from Bio-Rad and used to
equalize the protein concentration in all samples. Each lane
was then loaded with exactly 10μg of protein.
4.6. Statistical Analysis. The data are presented as mean ±
SEM. The signiﬁcance of the diﬀerences in mean values
for hemodynamics, infarction size, between groups was
evaluated by one-way ANOVA, followed by posthoc testing
(Newman-Keuls). Diﬀerences in SphK activity between WTOxidative Medicine and Cellular Longevity 7
and SphK2 KO tissues were evaluated by Student’s t-test.
P<. 05 was considered statistically signiﬁcant.
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